A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Merus B.V.
Merus B.V.
AstraZeneca
Johnson & Johnson Enterprise Innovation Inc.
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
R-Pharm
Merus B.V.
Merck Sharp & Dohme LLC
Incyte Corporation
Rakuten Medical, Inc.
EMD Serono
GlaxoSmithKline
Merck Sharp & Dohme LLC
AVEO Pharmaceuticals, Inc.
Rakuten Medical, Inc.
GlaxoSmithKline
Shanghai Miracogen Inc.
Soligenix
Bristol-Myers Squibb
CEL-SCI Corporation
Pfizer
Bristol-Myers Squibb
Sinocelltech Ltd.
Incyte Corporation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pierre Fabre Medicament
Sanofi
Merck KGaA, Darmstadt, Germany
Oncolytics Biotech
Merck KGaA, Darmstadt, Germany
Navidea Biopharmaceuticals
INSYS Therapeutics Inc
Daiichi Sankyo
AstraZeneca
Vical
Introgen Therapeutics